FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897550065> ?p ?o ?g. }

• W2897550065 endingPage "e650" @default.
• W2897550065 startingPage "e650" @default.
• W2897550065 abstract "The designation of high-intermediate risk in early stage endometrioid carcinoma of the uterus was supposed to identify patients who are at the highest risk of recurrence. The purpose of this study is to determine if the risk of relapse for some patients with high-intermediate risk endometrial carcinoma is similar to that of low-intermediate risk patients. We identified patients from our institutional database with intermediate risk endometrioid endometrial adenocarcinoma who were treated with adjuvant radiotherapy from 1992 to 2009. Rates of vaginal, pelvic, paraaortic and distant recurrence and disease free survival and overall survival were estimated using the Kaplan-Meier method and compared with log-rank testing. A total of 603 patients were identified with intermediate risk endometrioid endometrial carcinoma. Of these, 206 (34%) were high-intermediate risk and 397 (66%) were low-intermediate risk. Comparison of the risk of relapse between high-intermediate and low-intermediate risk groups was limited to patients with FIGO 2009 stage IA grade 1-3 and stage IB grade 1-2, because no patients with stage IB grade 3 or stage II cancers were low-intermediate risk. Of the 206 patients with high-intermediate risk, 144 (70%) were either stage IA (n = 68) or IB grade 1,2 (n =76). The actuarial risks of recurrence (any) at 5 years among these groups is shown in table 1. Within the high-intermediate risk group stage IA grade 1-3 and stage IB grade 1-2, 119/144 (83%) were treated with IVRT alone. In this subset, the 5 year risks of vaginal, pelvic, paraaortic and distant recurrence were 2.2 +/-1.5%, 3.6 +/- 1.8%, 1.9 +/- 1.3%, 7.8 +/- 2.7%. The disease free survival was 88.3 +/- 3.2% and the overall survival was 86.4 +/- 3.5%. Based on this study, risk of relapse is not high across the board in high-intermediate risk patients. In fact, a significant subset (70%) of patients with high-intermediate risk endometrioid adenocarcinoma has similar risk of relapse to patients with low-intermediate risk disease. Furthermore, many patients within that subset (119/144; 83%) can be treated with IVRT alone.Abstract TU_20_3519: Table 1Five year actuarial rates of recurrence (any) in patients with intermediate risk endometrioid adenocarcinoma.Low-int riskHi-int riskp-valueStage IA Grade 1-36.7% (95%CI 3.9- 9.5%) (n=362)9.7% (95%CI 2.1-17.3%) (n=68)0.50Stage IB Grade 1-25.8% (95%CI 0-13.8%) (n=35)8.3% (95%CI 1.3-15.3) (n=76)0.37 Open table in a new tab" @default.
• W2897550065 created "2018-10-26" @default.
• W2897550065 creator A5002011120 @default.
• W2897550065 creator A5020075785 @default.
• W2897550065 creator A5023685848 @default.
• W2897550065 creator A5031738512 @default.
• W2897550065 creator A5049069950 @default.
• W2897550065 creator A5067395984 @default.
• W2897550065 date "2018-11-01" @default.
• W2897550065 modified "2023-10-14" @default.
• W2897550065 title "Are All High-Intermediate Risk Early Stage Endometrioid Carcinomas of the Uterus Created Equal?" @default.
• W2897550065 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1766" @default.
• W2897550065 hasPublicationYear "2018" @default.
• W2897550065 type Work @default.
• W2897550065 sameAs 2897550065 @default.
• W2897550065 citedByCount "0" @default.
• W2897550065 crossrefType "journal-article" @default.
• W2897550065 hasAuthorship W2897550065A5002011120 @default.
• W2897550065 hasAuthorship W2897550065A5020075785 @default.
• W2897550065 hasAuthorship W2897550065A5023685848 @default.
• W2897550065 hasAuthorship W2897550065A5031738512 @default.
• W2897550065 hasAuthorship W2897550065A5049069950 @default.
• W2897550065 hasAuthorship W2897550065A5067395984 @default.
• W2897550065 hasConcept C121608353 @default.
• W2897550065 hasConcept C126322002 @default.
• W2897550065 hasConcept C143998085 @default.
• W2897550065 hasConcept C146357865 @default.
• W2897550065 hasConcept C151730666 @default.
• W2897550065 hasConcept C2777088508 @default.
• W2897550065 hasConcept C2777546739 @default.
• W2897550065 hasConcept C29456083 @default.
• W2897550065 hasConcept C71924100 @default.
• W2897550065 hasConcept C86803240 @default.
• W2897550065 hasConceptScore W2897550065C121608353 @default.
• W2897550065 hasConceptScore W2897550065C126322002 @default.
• W2897550065 hasConceptScore W2897550065C143998085 @default.
• W2897550065 hasConceptScore W2897550065C146357865 @default.
• W2897550065 hasConceptScore W2897550065C151730666 @default.
• W2897550065 hasConceptScore W2897550065C2777088508 @default.
• W2897550065 hasConceptScore W2897550065C2777546739 @default.
• W2897550065 hasConceptScore W2897550065C29456083 @default.
• W2897550065 hasConceptScore W2897550065C71924100 @default.
• W2897550065 hasConceptScore W2897550065C86803240 @default.
• W2897550065 hasIssue "3" @default.
• W2897550065 hasLocation W28975500651 @default.
• W2897550065 hasOpenAccess W2897550065 @default.
• W2897550065 hasPrimaryLocation W28975500651 @default.
• W2897550065 hasRelatedWork W1953419452 @default.
• W2897550065 hasRelatedWork W1999344589 @default.
• W2897550065 hasRelatedWork W2356105190 @default.
• W2897550065 hasRelatedWork W2407765299 @default.
• W2897550065 hasRelatedWork W2992256246 @default.
• W2897550065 hasRelatedWork W2998971914 @default.
• W2897550065 hasRelatedWork W3029372679 @default.
• W2897550065 hasRelatedWork W3106451637 @default.
• W2897550065 hasRelatedWork W4238850057 @default.
• W2897550065 hasRelatedWork W4361970035 @default.
• W2897550065 hasVolume "102" @default.
• W2897550065 isParatext "false" @default.
• W2897550065 isRetracted "false" @default.
• W2897550065 magId "2897550065" @default.
• W2897550065 workType "article" @default.